Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline augmentation in TRS
NCT02533232Phase 1Unknown
- Sponsor
- Pakistan Institute of Living and Learning
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia, schizoaffective disorder and schizophreniform disorder comparing Minocycline with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 3 months. Status: unknown.
02
Drugs
minocycline
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT02533232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533232.